Bio-Rad reported year-on-year revenue growth of 0.7% at constant currency, its first quarter of growth this year, and non-GAAP operating margin rose 1 point to 12.8%. Management expects full-year currency-neutral revenue decline around 1.25% and margin in the upper half of its 10%-12% range.
BIO is trading within a range we consider fairly valued.
Price
$386.48
Fair Value
LOCK|!^
Uncertainty
LOCK|D%
1-Star Price
^d?
5-Star Price
LOCK|mj
Economic Moat
LOCK|?^s
Capital Allocation
LOCK|@@kd!^z
Bulls Say, Bears Say
Bulls
Bio-Rad is a leader in niche areas including quality controls, antigens, and digital PCR, and it has a strong razor-and-blade model in clinical diagnostics.
Bears
Bio-Rad’s life science business currently faces a challenging environment due to funding cuts for US life sciences research and the potential for a weakening biotech funding environment.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.